[go: up one dir, main page]

PE20191502A1 - Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica - Google Patents

Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica

Info

Publication number
PE20191502A1
PE20191502A1 PE2019001004A PE2019001004A PE20191502A1 PE 20191502 A1 PE20191502 A1 PE 20191502A1 PE 2019001004 A PE2019001004 A PE 2019001004A PE 2019001004 A PE2019001004 A PE 2019001004A PE 20191502 A1 PE20191502 A1 PE 20191502A1
Authority
PE
Peru
Prior art keywords
diabetes
treat type
pharmaceutically acceptable
diabetic dyslipidemia
medical complex
Prior art date
Application number
PE2019001004A
Other languages
English (en)
Inventor
Ki Sook Park
Sung Won Kim
Ji Yoon Kim
Seok Cheol Yoo
Ri Sun Kim
Jae Soon Ahn
Hye Jin Yoon
Jong Hyuk Jung
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191502(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20191502A1 publication Critical patent/PE20191502A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a una combinacion que comprende gemigliptina, que es un inhibidor de peptidasa IV o una sal farmaceuticamente aceptable del mismo, y rosuvastatina, que es un inhibidor de la HMG-CoA reductasa o una sal farmaceuticamente aceptable del mismo. Ademas, puede comprender estabilizadores, aglutinantes, desintegrantes, deslizantes, agentes de carga y similares como excipientes farmaceuticamente aceptables. Dicha preparacion sirve para tratar eficazmente la diabetes mellitus tipo 2 y la dislipidemia en pacientes diabeticos.
PE2019001004A 2016-11-15 2017-11-15 Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica PE20191502A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160152195 2016-11-15
PCT/KR2017/012941 WO2018093144A1 (ko) 2016-11-15 2017-11-15 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제

Publications (1)

Publication Number Publication Date
PE20191502A1 true PE20191502A1 (es) 2019-10-22

Family

ID=62146049

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001004A PE20191502A1 (es) 2016-11-15 2017-11-15 Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica

Country Status (10)

Country Link
KR (1) KR102055894B1 (es)
CN (1) CN109996545A (es)
BR (1) BR112019009709A2 (es)
CO (1) CO2019005207A2 (es)
MX (1) MX2019005572A (es)
PE (1) PE20191502A1 (es)
PH (1) PH12019501028A1 (es)
RU (1) RU2721406C1 (es)
UA (1) UA122847C2 (es)
WO (1) WO2018093144A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874701A (zh) * 2025-01-14 2025-04-25 深圳格莱恩生物医药科技有限公司 一种吉格列汀马来酸盐晶体及其制备方法与应用
CN120004890B (zh) * 2025-02-17 2025-10-21 安徽峆一药业股份有限公司 一种吉格列汀盐酸盐微晶及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AP2007004234A0 (en) * 2005-04-22 2007-12-31 Alantos Pharm Holding Dipeptidyl peptidase-IV inhibitors
EP2464344A2 (en) * 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
CN107115530A (zh) * 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제
TWI606848B (zh) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
CN103494788B (zh) * 2013-10-10 2015-08-05 齐晓彤 瑞舒伐他汀钙片的药物组合物及其制备方法
CN104473929B (zh) * 2014-12-17 2018-05-29 深圳翰宇药业股份有限公司 一种西格列汀辛伐他汀缓释组合物

Also Published As

Publication number Publication date
CN109996545A (zh) 2019-07-09
CO2019005207A2 (es) 2019-08-20
UA122847C2 (uk) 2021-01-06
MX2019005572A (es) 2019-08-14
KR102055894B1 (ko) 2019-12-13
RU2721406C1 (ru) 2020-05-19
BR112019009709A2 (pt) 2019-08-13
WO2018093144A1 (ko) 2018-05-24
KR20180054500A (ko) 2018-05-24
PH12019501028A1 (en) 2020-01-20

Similar Documents

Publication Publication Date Title
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX378726B (es) Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX370361B (es) Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
PE20191502A1 (es) Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
CO2017004785A2 (es) N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a